Tag: diagnostic test

April 19, 2018

OpGen Completes Rapid Testing Clinical Trial in Colombia and Expands International Operations

OpGen (NASDAQ:OPGN) OpGen announced today that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic...
April 3, 2018

BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal

BriaCell Therapeutics Corp. ("BriaCell") (TSXV:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to...
March 27, 2018

BriaCell Completes Previously Announced Oversubscribed Non-Brokered Private Placement and Concurrent Investment With Leading U.S. Biotech Funds

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology,...
March 23, 2018

CareDx Reports Fourth Quarter and FY2017 Financial Results

CareDx (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for...
March 8, 2018

BriaCell Announces Proposed Investment by Leading Biotech Funds and Concurrent Non-Brokered Financing for aggregate gross proceeds of up to $4.8 Million

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology,...
February 8, 2018

Q Biomed Inc. Signs Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma

Q BioMed Inc. (OTCQB:QBIO), is pleased to announce an exclusive option agreement with Washington University in St. Louis.
January 31, 2018

BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT™

BriaCell Therapeutics Corp.("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, provides an update on...